Abbott Laboratories - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Abbott Laboratories

Top of Directory » All Categories » by Company » Abbott Laboratories



  • Effect of a Medical Food Supplement in Hospitalized Patients Recovering From Surgery

    Condition:   Hip Fracture
    Interventions:   Other: Medical Food Supplement;   Other: standard hospital food
    Sponsor:   Abbott Nutrition
    Recruiting - verified November 2009
  • Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

    Conditions:   Respiratory Syncytial Infection;   Prematurity;   Bronchopulmonary Dysplasia;   Chronic Heart Disease
    Intervention:   Biological: palivizumab
    Sponsor:   Abbott
    Not yet recruiting - verified November 2009
  • Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

    Conditions:   Coronary Artery Disease;   Chronic Kidney Disease;   Hypovitaminosis D;   Secondary Hyperparathyroidism
    Interventions:   Drug: paricalcitol;   Drug: placebo
    Sponsors:   Thomas Jefferson University;   Abbott
    Recruiting - verified November 2009
  • ABT-888 and Temozolomide for Metastatic Breast Cancer

    Conditions:   Breast Cancer;   Metastatic Breast Cancer
    Interventions:   Drug: ABT-888;   Drug: temozolomide
    Sponsors:   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Abbott
    Recruiting - verified November 2009
  • Fructooligosaccharide and Calcium Absorption in Adolescent Girls

    Condition:   Osteoporosis
    Intervention:   Dietary Supplement: Fructooligosaccharide
    Sponsors:   Purdue University;   Abbott Nutrition;   GTC Nutrition
    Recruiting - verified October 2009
  • A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

    Condition:   Healthy
    Intervention:   Drug: ABT-384
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

    Conditions:   Lymphoma;   Chronic Lymphocytic Leukemia;   Solid Tumors
    Interventions:   Drug: ABT-263;   Drug: erlotinib;   Drug: irinotecan
    Sponsor:   Abbott
    Recruiting - verified November 2009
  • Gene Therapy for the Treatment of Chronic Stable Angina

    Condition:   Myocardial Ischemia
    Intervention:   Genetic: VM202
    Sponsor:   ViroMed Co., Ltd.
    Not yet recruiting - verified October 2009
  • Metabolic Effects of Paricalcitol

    Condition:   Chronic Kidney Disease
    Interventions:   Drug: Paricalcitol;   Drug: Placebo
    Sponsors:   University of Washington;   Abbott
    Recruiting - verified October 2009
  • Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

    Conditions:   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
    Interventions:   Drug: ABT-869;   Drug: Sorafenib
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009
  • Artery Elasticity After Switch From Epzicom to Truvada

    Condition:   HIV Infections
    Intervention:   Drug: Tenofovir disoproxil
    Sponsor:   Minneapolis Medical Research Foundation
    Recruiting - verified October 2009
  • Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism

    Conditions:   Secondary Hyperparathyroidism;   Hemodialysis
    Interventions:   Drug: paricalcitol;   Drug: maxacalcitol
    Sponsors:   Abbott;   Abbott Japan Co.,Ltd
    Recruiting - verified October 2009
  • Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma

    Condition:   Asthma
    Interventions:   Drug: ABT-308;   Drug: ABT-308;   Drug: Placebo;   Drug: Placebo
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

    Condition:   Hepatitis C
    Interventions:   Drug: ABT-072;   Drug: Placebo
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

    Conditions:   Lymphoma;   Chronic Lymphocytic Leukemia;   Solid Tumors
    Interventions:   Drug: ABT-263;   Drug: ABT-263
    Sponsors:   Abbott;   Genentech
    Recruiting - verified October 2009
  • Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

    Conditions:   Chronic Kidney Disease;   Secondary Hyperparathyroidism
    Interventions:   Drug: Paricalcitol Arm;   Drug: Cinacalcet Arm
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

    Conditions:   HIV Infections;   Acquired Immunodeficiency Syndrome
    Intervention:   Drug: lopinavir/ritonavir plus maraviroc
    Sponsors:   Rodwick, Barry M., M.D.;   Abbott
    Not yet recruiting - verified September 2009
  • The Dual Antiplatelet Therapy Study (DAPT Study)

    Condition:   Coronary Artery Disease
    Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
    Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
    Recruiting - verified November 2009
  • A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

    Conditions:   Pharmacology;   Drug Safety;   Phase 1 Clinical Trials;   Pharmacokinetics
    Interventions:   Drug: ABT-384;   Drug: Matching placebo to ABT-384
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

    Conditions:   Breast Cancer;   Hot Flashes;   Menopausal Symptoms;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: flaxseed;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

    Condition:   Aged
    Interventions:   Other: Experimental Nutritional Powder Formula;   Other: Placebo comparator
    Sponsor:   Abbott Nutrition
    Recruiting - verified November 2009
  • Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

    Condition:   HIV-1 Infection
    Interventions:   Drug: Lopinavir/ritonavir;   Drug: HAART;   Drug: GSK2248761;   Drug: Placebo;   Drug: GSK2248761
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • Comparative Ca Absorption and Tolerance in Healthy Term Infants Fed Milk-based Formulas With Different Fat Blends

    Condition:   Infant
    Interventions:   Other: Infant Formula milk based;   Other: Infant formula milk based
    Sponsor:   Abbott Nutrition
    Not yet recruiting - verified November 2009
  • Study of Adalimumab in Subjects With Axial Spondyloarthritis

    Condition:   Axial Spondyloarthritis
    Interventions:   Drug: Adalimumab;   Drug: Placebo;   Drug: Open-label Adalimumab
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Collecting and Storing Samples From Patients With Lung Cancer

    Condition:   Lung Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

    Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Safety Study of ABT-263 in Combination With Carbo-taxol (Carboplatin/Paclitaxel) in Subjects With Solid Tumors

    Condition:   Solid Tumor
    Interventions:   Drug: ABT-263;   Drug: paclitaxel;   Drug: Carboplatin
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009
  • Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

    Conditions:   Secondary Hyperparathyroidism;   Renal Insufficiency, Chronic;   Parathyroid Hormone;   Hemodialysis;   Hypercalcemia
    Intervention:   Drug: Zemplar
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

    Condition:   Solid Tumor
    Interventions:   Drug: ABT-263;   Drug: gemcitabine
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009
  • Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Docetaxel in Subjects With Cancer

    Condition:   Solid Tumor
    Interventions:   Drug: ABT-263;   Drug: Docetaxel
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009
  • Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: cixutumumab;   Drug: Hedgehog antagonist GDC-0449;   Drug: cisplatin;   Drug: etoposide phosphate
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Small Cell Lung Cancer (SCLC)

    Condition:   Small Cell Lung Carcinoma
    Interventions:   Drug: ABT-263;   Drug: etoposide/cisplatin
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009
  • Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

    Conditions:   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dexamethasone;   Drug: gabapentin;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Adalimumab;   Drug: Placebo
    Sponsors:   Abbott;   Abbott Japan Co.,Ltd;   Eisai Limited
    Recruiting - verified October 2009
  • Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids

    Conditions:   Uterine Fibroids;   Uterine Myomas
    Intervention:   Device: Halt System
    Sponsor:   Halt Medical, Inc
    Recruiting - verified October 2009
  • Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

    Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Procedure: assessment of therapy complications
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: ABT-263;   Drug: FCR;   Drug: BR
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009
  • Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

    Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
    Intervention:   Drug: zoledronic acid
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Acute Pain Caused by Paclitaxel in Patients With Cancer

    Conditions:   Chemotherapeutic Agent Toxicity;   Neurotoxicity;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: paclitaxel;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: assessment of therapy complications
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

    Condition:   Ulcerative Colitis
    Interventions:   Biological: adalimumab;   Biological: placebo
    Sponsors:   Abbott;   Abbott Japan Co.,Ltd;   Eisai Limited
    Recruiting - verified October 2009
  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

    Condition:   Arthritis, Rheumatoid
    Interventions:   Biological: adalimumab;   Drug: methotrexate
    Sponsors:   Abbott;   Pharma Consulting Group
    Recruiting - verified November 2009
  • A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

    Conditions:   Skin Cancer;   Melanoma;   Metastatic Melanoma
    Interventions:   Drug: temozolomide;   Drug: ABT-888;   Drug: Placebo
    Sponsor:   Abbott
    Recruiting - verified November 2009
  • Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

    Condition:   Cervical Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

    Condition:   Chronic Plaque Psoriasis
    Intervention:   Biological: HUMIRA® (adalimumab)
    Sponsor:   Abbott
    Recruiting - verified October 2009
  • Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: lopinavir;   Drug: ritonavir
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
    Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Locally Recurrent, Stage IIIB, or Stage IV Breast Cancer

    Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Long-term Effects Secondary to Cancer Therapy in Adults;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
    Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Juvenile Idiopathic Arthritis (JIA) Registry

    Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: adalimumab;   Drug: Methotrexate
    Sponsor:   Abbott
    Recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials